ATE359367T1 - Ldl-rezeptor - Google Patents

Ldl-rezeptor

Info

Publication number
ATE359367T1
ATE359367T1 AT98917374T AT98917374T ATE359367T1 AT E359367 T1 ATE359367 T1 AT E359367T1 AT 98917374 T AT98917374 T AT 98917374T AT 98917374 T AT98917374 T AT 98917374T AT E359367 T1 ATE359367 T1 AT E359367T1
Authority
AT
Austria
Prior art keywords
gene
diseases
methods
diabetes
nucleic acid
Prior art date
Application number
AT98917374T
Other languages
German (de)
English (en)
Inventor
John Andrew Todd
John Wilfred Hess
Charles Thomas Caskey
Roger David Cox
David Gerhold
Holly Hammond
Patricia Hey
Yoshihiko Kawaguchi
Tony Raymond Merriman
Michael Lee Metzker
Yusuke Nakagawa
Michael Sean Phillips
Rebecca Christina Joan Twells
Original Assignee
Wellcome Trust Ltd As Trustee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Trust Ltd As Trustee, Merck & Co Inc filed Critical Wellcome Trust Ltd As Trustee
Application granted granted Critical
Publication of ATE359367T1 publication Critical patent/ATE359367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
AT98917374T 1997-04-15 1998-04-15 Ldl-rezeptor ATE359367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4355397P 1997-04-15 1997-04-15
US4874097P 1997-06-05 1997-06-05

Publications (1)

Publication Number Publication Date
ATE359367T1 true ATE359367T1 (de) 2007-05-15

Family

ID=26720554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98917374T ATE359367T1 (de) 1997-04-15 1998-04-15 Ldl-rezeptor

Country Status (9)

Country Link
US (1) US6545137B1 (enExample)
EP (1) EP0988379B1 (enExample)
JP (1) JP4271735B2 (enExample)
AT (1) ATE359367T1 (enExample)
AU (1) AU733722B2 (enExample)
CA (1) CA2286313C (enExample)
DE (1) DE69837542T2 (enExample)
ES (1) ES2285767T3 (enExample)
WO (1) WO1998046743A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244577B2 (en) * 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
FR2798138B1 (fr) * 1999-09-03 2004-05-21 Centre Nat Rech Scient Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante
BR0017197A (pt) * 2000-04-05 2003-01-14 Genome Therapeutics Corp Sequência de ácido nucleico, sequência de aminoácido, vetor de clonagem replicativo, célula hospedeira isolada vetor de expressão, métodos para testar uma substância como um agente terapêutico para modulação óssea em um hospedeiro, para identificar uma molécula e uma proteìna candidata envolvidas na modulação óssea, para testar quanto a atividade de hbm, para desenvolvimento farmacêutico para o tratamento de distúrbios do desenvolvimento ósseo, para tratar um distúrbio do desenvolvimento ósseo em um animal, para alterar o desenvolvimento ósseo em um hospedeiro, para tratar a osteoporose, para avaliar diagnóstico para uma predisposição genética a um distúrbio do desenvolvimento ósseo, para identificar uma predisposição genética para distúrbios do desenvolvimento ósseo, para expressar a proteìna de hbm em tecido ósseo, para amplificar um polimorfismo de nucleotìdeo, para identificar um elemento regulador de um gene de hbm e para modular densidade óssea em um paciente, ensaio de diagnóstico para distúrbios do desenvolvimento ósseo, cromossoma artificial bacteriano, segmento de ácido nucleico isolado, ácido nucleico, e, polipeptìdeo.
ES2290155T3 (es) * 2000-05-26 2008-02-16 Oscient Pharmaceuticals Corporation Regulacion de las tasas lipidicas por mediacion del gen zmax1 y del gen hbm.
WO2001091787A1 (en) 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
IL154473A0 (en) * 2000-08-18 2003-09-17 Proskelia Regulator gene and system useful for the diagnosis and therapy of osteoporosis
EP1434783A4 (en) * 2001-03-16 2006-06-07 Lilly Co Eli LP-mammalian proteins; RELATED REAGENTS
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
US20040221326A1 (en) * 2001-05-11 2004-11-04 Philip Babij Transgenic animal model of bone mass modulation
EP1483288A4 (en) * 2001-05-11 2005-09-21 Genome Therapeutics Corp HBM VARIANTS MODULATING BONE MASS AND LIPID LEVELS
EP1395285A4 (en) * 2001-05-17 2005-06-01 Genome Therapeutics Corp REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
WO2003015712A2 (en) 2001-08-20 2003-02-27 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin
GB2381790A (en) * 2001-09-26 2003-05-14 Glaxo Group Ltd LDL-receptor polypeptides
JP2005220022A (ja) * 2002-03-08 2005-08-18 Anges Mg Inc Ｗｎｔの新規作用、及び、疾患治療への応用
US7169559B2 (en) * 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
US20030219793A1 (en) * 2002-10-04 2003-11-27 Carulli John P. High bone mass gene of 11q13.3
WO2005049640A2 (en) 2003-11-17 2005-06-02 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
US7473770B2 (en) 2003-11-17 2009-01-06 Merck & Co., Inc. Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
EP1692167A2 (en) * 2003-11-24 2006-08-23 Gunnar Westin Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
MA48760A (fr) 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU1173995A (en) * 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
EP0758403B1 (en) * 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
JPH11508263A (ja) * 1995-06-23 1999-07-21 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ アグーチシグナルタンパク質およびそのペプチドの脱色活性
BR0017197A (pt) 2000-04-05 2003-01-14 Genome Therapeutics Corp Sequência de ácido nucleico, sequência de aminoácido, vetor de clonagem replicativo, célula hospedeira isolada vetor de expressão, métodos para testar uma substância como um agente terapêutico para modulação óssea em um hospedeiro, para identificar uma molécula e uma proteìna candidata envolvidas na modulação óssea, para testar quanto a atividade de hbm, para desenvolvimento farmacêutico para o tratamento de distúrbios do desenvolvimento ósseo, para tratar um distúrbio do desenvolvimento ósseo em um animal, para alterar o desenvolvimento ósseo em um hospedeiro, para tratar a osteoporose, para avaliar diagnóstico para uma predisposição genética a um distúrbio do desenvolvimento ósseo, para identificar uma predisposição genética para distúrbios do desenvolvimento ósseo, para expressar a proteìna de hbm em tecido ósseo, para amplificar um polimorfismo de nucleotìdeo, para identificar um elemento regulador de um gene de hbm e para modular densidade óssea em um paciente, ensaio de diagnóstico para distúrbios do desenvolvimento ósseo, cromossoma artificial bacteriano, segmento de ácido nucleico isolado, ácido nucleico, e, polipeptìdeo.

Also Published As

Publication number Publication date
CA2286313A1 (en) 1998-10-22
AU7061498A (en) 1998-11-11
AU733722B2 (en) 2001-05-24
CA2286313C (en) 2011-01-11
DE69837542T2 (de) 2008-01-31
DE69837542D1 (de) 2007-05-24
EP0988379A1 (en) 2000-03-29
WO1998046743A1 (en) 1998-10-22
JP4271735B2 (ja) 2009-06-03
US6545137B1 (en) 2003-04-08
JP2002501376A (ja) 2002-01-15
EP0988379B1 (en) 2007-04-11
ES2285767T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
DE69837542D1 (de) Ldl-rezeptor
Huizing et al. Hermansky–Pudlak syndrome: mutation update
Zmuda et al. Recent progress in understanding the genetic susceptibility to osteoporosis.
JP3675828B2 (ja) インターロイキン−１β転換酵素様アポトーシスプロテアーゼ−３および４
Srinivas et al. Oral lichen planus-Review on etiopathogenesis
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
HUP9902327A2 (hu) Humán gp39-elleni humanizált antitestek, az antitesteket tartalmazó készítmények és terápiás alkalmazásuk
Giurgea et al. TCF4 deletions in Pitt‐Hopkins syndrome
Jian-Gang et al. Apolipoprotein E and longevity among Han Chinese population
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
Ke et al. The regulation of self-tolerance and the role of inflammasome molecules
Hufnagl et al. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice
EP1556493A4 (en) NEW COMPLETE GENETIC DNA OF THE JAPANESE CEPHALITIS VIRUS, INFECTIOUS JEV CDNA FROM AND THEIR USE
WO1997044454A3 (en) Human phospholipase inhibitor
US20090285838A1 (en) Use of soluble cd164 in inflammation and autoimmune disorders
WO2000021983A3 (en) Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
WO2006099480A2 (en) Stress proteins and peptides and methods of use thereof
Chassin et al. The human homolog of ribosomal protein S18
WO2022253870A1 (en) Improved methods of treatment using immunogenic peptides
Liebers et al. Epitope mapping with peptides of Chi t I component III and immunomodulation of the Chi t immune response
Liebenberg Reattachment of coronal fragments: operative considerations for the repair of anterior teeth.
EP0808900A3 (en) Polynucleotides and polypeptides associated with benign prostatic hypertrophy
JPH10304883A (ja) 新規化合物
Cammarata‐Scalisi et al. Early severe pachyonychia congenita subtype PC-K6a with a novel mutation in the KRT6A gene.
ATE278011T1 (de) Human dnase ii

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties